October 2020 NDC-to-HCPCS Crosswalk Now Available
The quarterly NDC-to-HCPCS Crosswalk is now available for clinician-administered drug processing. The next new crosswalk will be available January 2021. Click here for information.
Branded Concerta Tablets Return to Non-Preferred Status on October 16, 2020
FirstCare follows the Texas VDP formulary. VDP temporarily removed the non-preferred status for brand Concerta products in the Stimulants drug class on April 23, 2020 in response to reported drug shortages. VDP will reverse this change in status because of sufficient availability in the market. VDP made this determination after verifying the current availability of the preferred Methylphenidate ER tablet products, as well as the non-preferred brand Concerta products through multiple sources such as ASHP, FDA, manufacturers, wholesalers, and pharmacies in various regions around Texas. VDP will restore the non-preferred status on the drugs below on October 16, 2020 because of sufficient product availability. For a complete list of all preferred products in the Stimulants drug class, refer to the July 2020 Preferred Drug List. Contact vdp-formulary@hhsc.state.tx.us (link sends e-mail) for questions or comments. For additional information and a list of preferred PDL NDCs, please click here.
July 2020 Preferred Drug List Revised September 8, 2020
The July 30, 2020 Texas Medicaid Preferred Drug List was revised, effective September 17, 2020. For additional information click here.
* Required field
ATTENTION: By clicking “Continue”, you will be leaving the FirstCare Medicare Dual SNP (HMO SNP) site pages. If you wish to remain on these pages, simply click “Cancel” or close this box.